Tweddle D A, Pinkerton C R, Lewis I J, Ellershaw C, Cole M, Pearson A D
Department of Paediatric Oncology, University of Newcastle, UK.
Med Pediatr Oncol. 2001 Jan;36(1):239-42. doi: 10.1002/1096-911X(20010101)36:1<239::AID-MPO1058>3.0.CO;2-G.
This paper reports the toxicity of OPEC/OJEC chemotherapy in stage 4 neuroblastoma patients over 1 year of age.
Ninety-five patients with stage 4 neuroblastoma received alternating courses of OPEC/OJEC--vincristine 1.5 mg/m2 (O), cisplatin 80 mg/m2 (P), etoposide 200 mg/m2 (E), cyclophosphamide 600 mg/m2 (C), and carboplatin 500 mg/m2 (J), every 21 days if there was haematological recovery.
Seventy out of ninety-five (74%) patients completed seven or more courses and were evaluable for toxicity. Of these 70 patients, 33% had more than three episodes of fever and sepsis, 35% required more than five blood or platelet transfusions, 36% had grade 2 or more gastrointestinal toxicity and 9% had neurotoxicity. There was a median reduction in GFR of 32 ml/min/1.73 m2 (-46 to 134) and there was one toxic death.
OPEC/OJEC is a well-tolerated therapy for stage 4 neuroblastoma over 1 year of age.
本文报告了1岁以上4期神经母细胞瘤患者接受OPEC/OJEC化疗的毒性。
95例4期神经母细胞瘤患者接受OPEC/OJEC交替疗程——长春新碱1.5mg/m²（O）、顺铂80mg/m²（P）、依托泊苷200mg/m²（E）、环磷酰胺600mg/m²（C）和卡铂500mg/m²（J），如果血液学指标恢复，则每21天进行一次。
95例患者中有70例（74%）完成了七个或更多疗程并可评估毒性。在这70例患者中，33%有三次以上发热和败血症发作，35%需要五次以上输血或血小板输注，36%有2级或更严重的胃肠道毒性，9%有神经毒性。肾小球滤过率中位数下降32ml/min/1.73m²（-46至134），有1例毒性死亡。
OPEC/OJEC是1岁以上4期神经母细胞瘤耐受性良好的治疗方法。
